Skip to main content

Table 1 Clinical and biochemical parameters during different study periods

From: Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels

  

Placebo

ARB

ARB + HCT

Systolic blood pressure (mmHg)

RS

143 (4)

135 (3)†

125 (3)†‡

LS

136 (3)*

128 (3)*†

121 (2)†‡

Diastolic blood pressure (mmHg)

RS

86 (2)

80 (2)†

75 (1)†‡

LS

83 (1)*

78 (1)†

74 (1)†‡

Plasma potassium concentration (mmol/l)

RS

4.3 ± 0.1

4.4 ± 0.1

4.0 ± 0.1†‡

LS

4.3 ± 0.1

4.5 ± 0.1†

4.0 ± 0.1†‡

24 h sodium excretion (mmol/day)

RS

200 ± 10

197 ± 11

193 ± 11

LS

89 ± 10*

92 ± 8*

93 ± 8*

Creatinine clearance (ml/min)

RS

85 (73–98)

90 (77–106)

81 (69–95)‡

LS

80 (67–94)

79 (67–93)*

72 (61–85)*

Proteinuria (g/day)

RS

3.4 (2.6–4.3)

2.3 (1.8–3.0)†

1.3 (1.0–1.7)†‡

LS

2.3 (1.7–3.1)*

1.3 (0.9–1.7)†*

0.9 (0.6–1.2)*†‡

Active plasma renin concentration (ng AI/ml x h)

RS

15 (12–18)

33 (23–45)†

64 (47–87)†‡

LS

19 (15–23)

51 (38–70)*†

130 (103–163)*†‡

Plasma aldosterone concentration (ng/l)

RS

66 (48–91)

57 (41–79)

96 (74–125)‡

LS

106 (73–152)

113 (86–149)*

164 (129–207)*†‡

Aldosterone-to-renin ratio (ng/ng AI × h)

RS

19 (13–26)

7 (4–11)†

6 (4–9)†

LS

22 (14–32)

9 (6–13)†

5 (4–7)†‡

  1. ARB angiotensin receptor blocker (losartan 100 mg/day), HCT hydrochlorothiazide (25 mg/day), RS regular sodium intake, LS low sodium intake
  2. *P < 0.05 vs regular sodium on same treatment (effect of LS)
  3. † P < 0.05 vs placebo on same sodium diet
  4. ‡ P < 0.05 vs ARB on same sodium diet (effect of HCT)